Pharmacopsychiatry 2007; 40(1): 37-38
DOI: 10.1055/s-2006-951609
Letter

© Georg Thieme Verlag KG Stuttgart · New York

A Case of Aripiprazole-induced Mania

R. Traber 1 , R. Schneiter 1 , J. Modestin 1
  • 1University of Zurich, Department of Psychiatry, Burghölzli Hospital, Zurich, Switzerland
Weitere Informationen

Publikationsverlauf

received 21. 6. 2006 revised 8. 8. 2006

accepted 11. 8. 2006

Publikationsdatum:
27. Februar 2007 (online)

Introduction

Aripiprazole is a novel atypical neuroleptic. It acts as a partial agonist at the dopamine D2 receptor, as a partial agonist at the 5-HT1A receptor, and as an antagonist at the 5-HT2A receptor. Clinical trials have established its clinical efficacy and favorable tolerability profile [5] [16]. Nevertheless, infrequent undesirable adverse events are often encountered during wide-scale everyday clinical use. Induction of mania, described for almost all second-generation neuroleptics [2] [3] [11] [15] [17], may be one of the rare adverse events of aripiprazole therapy.

We present a case of an induction of mania after initiation of aripiprazole treatment in a male patient with chronic schizophrenia who had never presented affective symptoms and had been without continuous medication for several years.

References

  • 1 American Psychiatric Association .Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Washington DC: American Psychiatric Association 1994
  • 2 Aubry JM, Simon AE, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.  J Clin Psychiatry. 2000;  61 649-654
  • 3 Baldassano CF, Ballas C, Datto SM, Kim D, Littman L, O'Reardon J, Rynn MA. Ziprasidone-associated mania: a case series and review of the mechanism.  Bipol Disorder. 2003;  5 72-75
  • 4 Burris KD, Molski TF, Xu C, Ryan El, Tottori K, Kikiuchi T. et al . Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.  J Pharmacol Exp Ther. 2002;  302 381-389
  • 5 Carson WH, McQuade RD, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol.  Schizophr Res. 2001;  49 ((Suppl 1)) 221-222
  • 6 Hugenholtz GWK, Herrdink ER, Meijer WE, Stolker JJ, Egberts ACG, Nolen WA. Reasons for switching between antipsychotics in daily clinical practice.  Pharmacopsychiatry. 2005;  38 122-124
  • 7 Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H. et al . Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.  J Psychopharmacol. 2004;  18 375-383
  • 8 Jordan S, Koprivica V, Chen R, Tottori K, Kickuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor.  Eur J Pharmacol. 2002;  441 137-140
  • 9 Keck PE, Marcus R, Tourkodimitris S, Ali M, Liebeskind A, Saha A, Ingenito G. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.  Am J Psychiatry. 2003;  160 1651-1658
  • 10 Kelland MD, Freeman AS, Chiodo LA. Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons.  J Pharmacol Exp Ther. 1990;  253 803-811
  • 11 Lane HY, Lin YC, Chang WH. Mania induced by risperidone: dose related?.  J Clin Psychiatry. 1998;  59 85-86
  • 12 Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ. et al . Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.  Schizophr Res. 2003;  61 123-136
  • 13 McDaniel JS, Ninan PT, Magnuson JV. Possible induction of mania by buspirone.  Am J Psychiatry. 1990;  147 125-126
  • 14 Millan MJ. Improving the treatment of schizophrenia: focus on serotonin (5-HT)1A receptors.  J Pharmacol Exp Ther. 2000;  295 853-861
  • 15 Murphy BP. Amisulpride-induced mania in a patient with schizophrenia.  Br J Psychiatry. 2003;  183 172
  • 16 Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E. et al . Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.  Arch Gen Psychiatry. 2003;  60 681-690
  • 17 Rachid R, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases.  J Clin Psychiatry. 2004;  65 1537-1545
  • 18 Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR. et al . Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.  Neuropsychopharmacology. 2003;  28 1400-1411
  • 19 Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity, sensitivity.  Br J Psychiatry. 1978;  133 423-435

Correspondence

J. Modestin

University of Zurich·Department of Psychiatry

Burghölzli Hospital

Lenggstrasse 31

CH-8029 Zurich

Switzerland

Telefon: +41/44/384 26 70

Fax: +41/44/384 27 19

eMail: modestin@bli.unizh.ch